Agilent Technologies, IncNYSE: A
Health Care · Life Sciences Tools & Services
$127.36
+2.44%
Vol: 1.9M
Research Digest
Thursday, June 18, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Agilent FQ2 results May 27; TSA contract for World Cup airport securityNeutral▶
Awarded TSA contract for Bulk Alarm Resolution Technology (BRT) deployment at US airport security checkpoints in FIFA World Cup host cities. Named Michael Buckner as Chief Legal Officer on May 4. Participated in Jefferies Global Healthcare Conference May 11. FQ2 2026 earnings release scheduled for after market close Wednesday, May 27 with 1:30 PM PDT call. Market cap $31.86B mid-May reflecting -17.4% change. Patent decision in Agilent v. Synthego (May 14 analysis) on enablement standards. Analysts project 55% profit growth over next few years.
May 20Agilent won a TSA contract on May 19 to deploy Bulk Alarm Resolution Technology at FIFA World Cup 2026 U.S. host city airports ahead of its May 27 fiscal Q2 earnings release.Positive▶
Agilent announced on May 19 a U.S. TSA contract to supply its next-generation Bulk Alarm Resolution Technology (BRT) for screening larger quantities of liquids, powders, and solids at airport checkpoints in FIFA World Cup 2026 host cities. The contract win provides incremental government revenue visibility and validates Agilent's diagnostics tech platform beyond core life sciences. It comes ahead of fiscal Q2 2026 earnings on May 27, where shares enter trading at $110.86, just 3.8% above the 52-week low and down 19% YTD. The catalyst is modest in size but offers a positive headline into the print at a weak technical level. Analyst sentiment has been mixed but recent upgrades cite improved earnings estimates.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours. Agilent is heading into its Q2 FY2026 earnings release scheduled for May 27.
May 15Agilent named Michael Buckner Chief Legal Officer on May 4 and will participate in the Jefferies Global Healthcare Conference May 11 ahead of Q2 FY26 earnings on May 27; FDA recently granted exclusive approval for its PD-L1 assay.Positive▶
Agilent Technologies named Michael Buckner as Chief Legal Officer effective May 4, 2026. The company participated in the Jefferies Global Healthcare Conference on May 11 and will report Q2 FY2026 results after market close on May 27. FY2026 guidance is maintained at 4-6% core growth and EPS of $5.90-$6.04, with margin expansion expected as tariff headwinds ease. The book-to-bill ratio has exceeded 1.0x with year-over-year order growth for the first time in 7 quarters, and clinical business orders are up roughly 50%. The FDA granted exclusive approval for Agilent's PD-L1 assay, enhancing its precision oncology footprint. Analyst consensus is Strong Buy with median PT $159.50 (range $140-$185) across 29 Wall Street analysts. Risk: tariff exposure on instrument shipments, near-term FX volatility.
May 14Agilent names Michael Buckner Chief Legal Officer on May 4 and confirms Q2 FY26 earnings release for May 27 after the close.Neutral▶
Agilent Technologies announced on May 4, 2026 that it has named Michael Buckner as Chief Legal Officer. The company will release Q2 fiscal 2026 financial results after the close on Wednesday, May 27, followed by a conference call at 1:30 p.m. PDT. Agilent participated in the Jefferies Global Healthcare Conference on May 11. The company is expanding its role in RNA technology with a new licensing agreement and recently received FDA approval (in March 2026) for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify esophageal/GEJ carcinoma patients eligible for KEYTRUDA. Trailing twelve-month revenue stands at $6.95B with net income of $1.30B; market cap is $32.65B with beta of 1.22. Analysts project ~55% profit growth over the next several years.
May 13No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 12Agilent Technologies to report Q2 FY26 results May 27 amid FDA approval and Biocare Medical acquisition plansPositive▶
Agilent Technologies will release Q2 fiscal 2026 financial results after the market close on May 27 with a 1:30 p.m. PDT conference call. Recent strategic moves include plans to acquire Biocare Medical (a global clinical/research pathology leader) and a licensing agreement with Cirena for long RNA technology to expand its genome editing role. The company received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic for KEYTRUDA in esophageal/GEJ carcinoma. New product launches include the BioTek Cytation 9 Cell Imaging Multimode Reader. Agilent also opened a customer experience center in Mumbai and partnered with OmixAI for AI-driven proteomics in South Korea. Analysts project 55% profit growth over coming years.
May 11Agilent named Michael Buckner as new Chief Legal Officer effective May 4, succeeding Bret DiMarco ahead of Q2 FY26 earnings on May 27Positive▶
Agilent Technologies appointed Michael Buckner as Chief Legal Officer effective May 4, 2026, succeeding Bret DiMarco who resigned per a previously disclosed transition agreement. Buckner joins from Danaher Corp where he served as VP, Deputy General Counsel and Chief M&A Counsel, bringing nearly 30 years of complex transactions, governance and regulatory experience. Agilent will release Q2 FY2026 financial results after market close on May 27. The company recently received FDA approval for PD-L1 IHC 22C3 pharmDx (Code SK006) as a companion diagnostic for esophageal/GEJ carcinoma KEYTRUDA eligibility. Agilent also expanded its genomic tools licensing through a Cirena deal and launched the BioTek Cytation 9 cell imaging multimode reader. Analysts project ~55% profit growth over the next few years.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $466.53 | +1.05% | +2.8% | 17.1x | 0.87 | $172.7B |
| DHRDANAHER | $177.74 | -0.01% | +3.5% | 19.1x | 0.83 | $125.4B |
| AAGILENT | $127.36 | +2.44% | +11.7% | 19.2x | 1.26 | $35.9B |
| WATWATERS | $356.50 | -0.14% | +4.1% | 21.6x | 1.20 | $34.9B |
| IQVIQVIA | $168.20 | -1.45% | -2.2% | 11.8x | 1.22 | $28.0B |
| MTDMETTLER | $1,150.03 | +1.81% | +5.7% | 22.3x | 1.26 | $23.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.